Latency to paroxetine-induced anxiolysis in the rat is reduced by co-administration of the 5-HT(1A) receptor antagonist WAY100635

British Journal of Pharmacology

Volumn 130, Issue 7, 2000, Pages 1713-1719

  Duxon, M S ^a   Starr, K R ^a   Upton, N ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

5 HT; 5 HT(1A); 5 hydroxytryptamine; Anxiety; Anxiolysis; Paroxetine; Serotonin; SSRI; WAY100635

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PAROXETINE; SEROTONIN 1A ANTAGONIST;

ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; LOCOMOTION; MALE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; SOCIAL INTERACTION; TRANQUILIZING ACTIVITY;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; HYPERKINESIS; INTERPERSONAL RELATIONS; MALE; PAROXETINE; PIPERAZINES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN ANTAGONISTS;

EID: 0033865792     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0703496     Document Type: Article

References (33)

1. ARTIGAS, F. (1993). 5-HT and antidepressants: new views from microdialysis studies. Trends Pharmacol Sci., 14, 262.
2. ARTIGAS, F., PEREZ, V. & ALVAREZ, E. (1994). Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch. Gen. Psychiatry, 51, 248-251.
3. BASCARA, L. (1989). A double blind study to compare the effectiveness and tolerability of paroxetine and amitriptyline in depressed patients. Acta Psychiatr. Scand., 80 (Suppl. 350): 141-142.
4. BERMAN, R.M., ANAND, A., CAPPIELLO, A., MILLER, H.L., HU, X.S., OREN, D.A. & CHARNEY, D.S. (1999). The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial. Biol. Psychiatry, 45, 1170-1177.
5. BERMAN, R.M., DARNELL, A.M., MILLER, H.L., ANAND, A. & CHARNEY, D.S. (1997). Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am. J. Psychiatry, 154, 37-43.
6. BERTON, O., DURAND, M., AGUERRE, S., MORMEDE, P. & CHAOULOFF, F. (1999). Behavioral, neuroendocrine and serotonergic consequences of single social defeat and repeated fluoxetine pretreatment in the Lewis rat strain. Neuroscience, 92, 327-341.
7. BLIER, P. & BERGERON, R. (1995). Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J. Clin. Psychopharmacol., 15, 217-222.
8. COHN, J.B. & WILCOX, C.S. (1992). Paroxetine in major depression: a double blind trial with imipramine and placebo. J. Clin. Psychiatry, 53, 52-56.
9. 1A antagonist, WAY-100635, alone, and in combination with paroxetine, on olfactory bulbectomy and 8-OH-DPAT-induced changes in the rat. Pharmacol. Biochem. Behav., 63, 333-338.
10. DUNBAR, G.C., COHN, J.B., FABRE, L.F., FEIGHNER, J.P., FIEVE, R.R., MENDELS, J. & SHRIVASTAVA, R.K. (1991). A comparison of paroxetine, imipramine and placebo in depressed out-patients. Br. J. Pharmacol., 159, 394-398.
11. FEIGHNER, J.P. & BOYER, W.F. (1992). Paroxetine in the treatment of depression: A comparison with imipramine and placebo. J. Clin. Psychiatry, 53, 44-47.
12. FILE, S.E. (1980). The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. J. Neurosci. Methods, 2, 219-238.
13. FILE, S.E. & HYDE, J.R. (1978). Can social interaction be used to measure anxiety? Br. J. Pharmacol., 62, 19-24.
14. FILE, S.E. & HYDE, J.R. (1979). A test of anxiety that distinguishes between the actions of benzodiazepines and those of other minor tranquilisers and of stimulants. Pharmacol. Biochem. Behav., 11, 65-69.
15. 1A receptor antagonist. Behav. Brain Res., 73, 337-353.
16. 1A receptor antagonist, WAY-100635. Eur. J. Pharmacol., 281, 81-88.
17. 1A receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. Br. J. Pharmacol., 115, 1064-1070.
18. GRIEBEL, G., BLANCHARD, D.C., AGNES, R.S. & BLANCHARD, R.J. (1995). Differential modulation of antipredator defensive behavior in Swiss-Webster mice following acute or chronic administration of imipramine and fluoxetine. Psychopharmacology, 120, 57-66.
19. GRIEBEL, G., MOREAU, J.L., JENCK, F., MISSLIN, R. & MARTIN, J.R. (1994). Acute and chronic treatment with 5-HT reuptake inhibitors differentially modulate emotional responses in anxiety models in rodents. Psychopharmacology, 113, 463-470.
20. HOLLANDER, E., DECARIA, C., GULLY, R., NITESCU, A., SUCKOW, R.F., GORMAN, J.M., KLEIN, D.F. & LIEBOWITZ, M.R. (1991). Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to metachlorophenylpiperazine in obsessive-compulsive disorder. Psychiatry Res., 36, 1-17.
21. 2C receptor antagonist. Neuropharmacology, 36, 609-620.
22. 2C,2B receptor antagonist. Br. J. Pharmacol., 111, 797-802.
23. KIEV, A. (1992). A double-blind, placebo-controlled study of paroxetine in depressed outpatients. J. Clin. Psychiatr., 53, 27-29.
24. LIGHTOWLER, S., KENNETT, G.A., WILLIAMSON, I.J., BLACKBURN, T.P. & TULLOCH, I.F. (1994). Anxiolytic-like effect of paroxetine in a rat social interaction test. Pharmacol. Biochem. Behav., 49, 281-285.
25. 1A receptor antagonist, WAY-100635. Behav. Pharmacol., 8, 585-606.
26. MONTGOMERY, S.A. (1999). New developments in the treatment of depression. J. Clin. Psychiatry, 60 (Suppl. 14): 10-15; discussion 31-35.
27. QUESTED, D.J., SARGENT, P.A. & COWEN, P.J. (1997). SSRI treatment decreases prolactin and hyperthermic responses to mCPP. Psychopharmacology, 133, 305-308.
28. RICKELS, K., AMSTERDAM, J., CLARY, C., FOX, I., SCHWEIZER, E. & WEISE, C. (1989). A plecebo-controlled, double-blind, clinical trial of paroxetine in depressed outpatients. Acta Psychiatr. Scand., 80 (Suppl. 350): 117-123.
29. THOMAS, D.R., NELSON, D.R. & JOHNSON, A.M. (1987). Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology, 93, 193-200.
30. TO, C.T., ANHEUER, Z.E. & BAGDY, G. (1999). Effects of acute and chronic fluoxetine treatment of CRH-induced anxiety. Neuroreport, 10, 553-555.
31. TO, C.T. & BAGDY, G. (1999). Anxiogenic effect of central CCK administration is attenuated by chronic fluoxetine or ipsapirone treatment. Neuropharmacology, 38, 279-282.
32. TRICKLEBANK, M.D., FORLER, C. & FOZARD, J.R. (1984). The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino)tetralin in the rat. Eur. J. Pharmacol., 106, 271-282.
33. ZOHAR, J., INSEL, T.R., ZOHAR-KADOUCH, R.C., HILL, J.L. & MURPHY, D.L. (1988). Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment. Arch. Gen. Psychiatry, 45, 167-172.